2783 related articles for article (PubMed ID: 33689159)
1. SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19.
Glück V; Grobecker S; Tydykov L; Salzberger B; Glück T; Weidlich T; Bertok M; Gottwald C; Wenzel JJ; Gessner A; Schmidt B; Peterhoff D
Infection; 2021 Aug; 49(4):739-746. PubMed ID: 33689159
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection.
Zervou FN; Louie P; Stachel A; Zacharioudakis IM; Ortiz-Mendez Y; Thomas K; Aguero-Rosenfeld ME
J Med Virol; 2021 Sep; 93(9):5409-5415. PubMed ID: 33932299
[TBL] [Abstract][Full Text] [Related]
3. Closing the serological gap in the diagnostic testing for COVID-19: The value of anti-SARS-CoV-2 IgA antibodies.
Infantino M; Manfredi M; Grossi V; Lari B; Fabbri S; Benucci M; Fortini A; Damiani A; Mobilia EM; Panciroli M; Pancani S; Pesce G
J Med Virol; 2021 Mar; 93(3):1436-1442. PubMed ID: 32790181
[TBL] [Abstract][Full Text] [Related]
4. Analytical and clinical validation of an ELISA for specific SARS-CoV-2 IgG, IgA, and IgM antibodies.
Tré-Hardy M; Wilmet A; Beukinga I; Favresse J; Dogné JM; Douxfils J; Blairon L
J Med Virol; 2021 Feb; 93(2):803-811. PubMed ID: 32667733
[TBL] [Abstract][Full Text] [Related]
5. Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection.
Kučinskaitė-Kodzė I; Simanavičius M; Šimaitis A; Žvirblienė A
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835119
[TBL] [Abstract][Full Text] [Related]
6. Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients.
Guo Y; Li T; Xia X; Su B; Li H; Feng Y; Han J; Wang X; Jia L; Bao Z; Li J; Liu Y; Li L
Front Immunol; 2021; 12():723585. PubMed ID: 34489974
[TBL] [Abstract][Full Text] [Related]
7. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
[TBL] [Abstract][Full Text] [Related]
8. Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak.
Brandstetter S; Roth S; Harner S; Buntrock-Döpke H; Toncheva AA; Borchers N; Gruber R; Ambrosch A; Kabesch M
Pediatr Allergy Immunol; 2020 Oct; 31(7):841-847. PubMed ID: 32413201
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic performance of four SARS-CoV-2 antibody assays in patients with COVID-19 or with bacterial and non-SARS-CoV-2 viral respiratory infections.
Huber T; Steininger P; Irrgang P; Korn K; Tenbusch M; Diesch K; Achenbach S; Kremer AE; Werblow M; Vetter M; Bogdan C; Held J
Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1983-1997. PubMed ID: 34109500
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 antibody kinetics in blood donors with a previously positive SARS-CoV-2 antibody test within a seroprevalence survey.
Levring MB; Holm DK; Nilsson AC; Bauer JM; Jensen IS; Davidsen JR; Rasmussen LD; Sprogøe U; Lillevang ST
J Med Virol; 2022 Apr; 94(4):1711-1716. PubMed ID: 34845745
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of serum IgM and IgG antibodies in COVID-19 patients by enzyme linked immunosorbent assay.
Zhou C; Bu G; Sun Y; Ren C; Qu M; Gao Y; Zhu Y; Wang L; Sun L; Liu Y
J Med Virol; 2021 May; 93(5):2857-2866. PubMed ID: 33331654
[TBL] [Abstract][Full Text] [Related]
12. Validation of a combined ELISA to detect IgG, IgA and IgM antibody responses to SARS-CoV-2 in mild or moderate non-hospitalised patients.
Cook AM; Faustini SE; Williams LJ; Cunningham AF; Drayson MT; Shields AM; Kay D; Taylor L; Plant T; Huissoon A; Wallis G; Beck S; Jossi SE; Perez-Toledo M; Newby ML; Allen JD; Crispin M; Harding S; Richter AG
J Immunol Methods; 2021 Jul; 494():113046. PubMed ID: 33775672
[TBL] [Abstract][Full Text] [Related]
13. A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization.
Peterhoff D; Glück V; Vogel M; Schuster P; Schütz A; Neubert P; Albert V; Frisch S; Kiessling M; Pervan P; Werner M; Ritter N; Babl L; Deichner M; Hanses F; Lubnow M; Müller T; Lunz D; Hitzenbichler F; Audebert F; Hähnel V; Offner R; Müller M; Schmid S; Burkhardt R; Glück T; Koller M; Niller HH; Graf B; Salzberger B; Wenzel JJ; Jantsch J; Gessner A; Schmidt B; Wagner R
Infection; 2021 Feb; 49(1):75-82. PubMed ID: 32827125
[TBL] [Abstract][Full Text] [Related]
14. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19.
Cervia C; Nilsson J; Zurbuchen Y; Valaperti A; Schreiner J; Wolfensberger A; Raeber ME; Adamo S; Weigang S; Emmenegger M; Hasler S; Bosshard PP; De Cecco E; Bächli E; Rudiger A; Stüssi-Helbling M; Huber LC; Zinkernagel AS; Schaer DJ; Aguzzi A; Kochs G; Held U; Probst-Müller E; Rampini SK; Boyman O
J Allergy Clin Immunol; 2021 Feb; 147(2):545-557.e9. PubMed ID: 33221383
[TBL] [Abstract][Full Text] [Related]
15. Antibody (IgA, IgG, and IgG Subtype) Responses to SARS-CoV-2 in Severe and Nonsevere COVID-19 Patients.
Patil HP; Rane PS; Shrivastava S; Palkar S; Lalwani S; Mishra AC; Arankalle VA
Viral Immunol; 2021 Apr; 34(3):201-209. PubMed ID: 33656935
[TBL] [Abstract][Full Text] [Related]
16. Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples.
Mazzini L; Martinuzzi D; Hyseni I; Benincasa L; Molesti E; Casa E; Lapini G; Piu P; Trombetta CM; Marchi S; Razzano I; Manenti A; Montomoli E
J Immunol Methods; 2021 Feb; 489():112937. PubMed ID: 33253698
[TBL] [Abstract][Full Text] [Related]
17. Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019.
Kowitdamrong E; Puthanakit T; Jantarabenjakul W; Prompetchara E; Suchartlikitwong P; Putcharoen O; Hirankarn N
PLoS One; 2020; 15(10):e0240502. PubMed ID: 33035234
[TBL] [Abstract][Full Text] [Related]
18. Serum IgG anti-SARS-CoV-2 Binding Antibody Level Is Strongly Associated With IgA and Functional Antibody Levels in Adults Infected With SARS-CoV-2.
Ye X; Angelo LS; Nicholson EG; Iwuchukwu OP; Cabral de Rezende W; Rajan A; Aideyan LO; McBride TJ; Bond N; Santarcangelo P; Rayford YJ; Ferlic-Stark L; Fragoso S; Momin Z; Liu H; Truong K; Lopez B; Conner ME; Rice AP; Kimata JT; Avadhanula V; Piedra PA
Front Immunol; 2021; 12():693462. PubMed ID: 34691016
[TBL] [Abstract][Full Text] [Related]
19. Response kinetics of different classes of antibodies to SARS-CoV2 infection in the Japanese population: The IgA and IgG titers increased earlier than the IgM titers.
Kurano M; Morita Y; Nakano Y; Yokoyama R; Shimura T; Qian C; Xia F; He F; Zheng L; Ohmiya H; Kishi Y; Okada J; Yoshikawa N; Nakajima K; Nagura Y; Okazaki H; Jubishi D; Moriya K; Seto Y; Yasui F; Kohara M; Wakui M; Kawamura T; Kodama T; Yatomi Y
Int Immunopharmacol; 2022 Feb; 103():108491. PubMed ID: 34954559
[TBL] [Abstract][Full Text] [Related]
20. Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection.
Siracusano G; Brombin C; Pastori C; Cugnata F; Noviello M; Tassi E; Princi D; Cantoni D; Malnati MS; Maugeri N; Bozzi C; Saretto G; Clementi N; Mancini N; Uberti-Foppa C; Temperton N; Bonini C; Di Serio C; Lopalco L
Front Immunol; 2021; 12():772239. PubMed ID: 34804064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
